Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares RepurchasedWages, Salaries and Other
Ratios

BridgeBio Pharma (BBIO) Long-Term Debt Repayments (2019 - 2025)

Historic Long-Term Debt Repayments for BridgeBio Pharma (BBIO) over the last 4 years, with Q1 2025 value amounting to $459.0 million.

  • BridgeBio Pharma's Long-Term Debt Repayments fell 304.53% to $459.0 million in Q1 2025 from the same period last year, while for Jun 2025 it was $459.0 million, marking a year-over-year decrease of 304.53%. This contributed to the annual value of $473.4 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q1 2025, BridgeBio Pharma's Long-Term Debt Repayments is $459.0 million, which was down 304.53% from $473.4 million recorded in Q1 2024.
  • In the past 5 years, BridgeBio Pharma's Long-Term Debt Repayments registered a high of $473.4 million during Q1 2024, and its lowest value of $106.0 million during Q4 2021.
  • Moreover, its 3-year median value for Long-Term Debt Repayments was $459.0 million (2025), whereas its average is $346.1 million.
  • Over the last 5 years, BridgeBio Pharma's Long-Term Debt Repayments had its largest YoY gain of 304.53% in 2025, and its largest YoY loss of 304.53% in 2025.
  • BridgeBio Pharma's Long-Term Debt Repayments (Quarter) stood at $106.0 million in 2021, then surged by 346.57% to $473.4 million in 2024, then dropped by 3.05% to $459.0 million in 2025.
  • Its Long-Term Debt Repayments was $459.0 million in Q1 2025, compared to $473.4 million in Q1 2024 and $106.0 million in Q4 2021.